[1] GARCIA-TSAO G, SANYAL AJ, GRACE ND, et al.Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Hepatology, 2007, 46(3): 922-938 [2] WANG DY.Srudy on definition and scope of adverse drug reaction surveillance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(12): 732-738. [3] TIEU C, BREDER CD.A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries[J]. Drug Saf, 2018, 41(12): 1375-1385. [4] CHENG JJ, WANG Z.Grading criteria for severity of adverse drug reaction damage and its bibliometric analysis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2019, 19(4): 487-490. [5] LI J, DU H.Epidemiological analysis of patients with liver disease admitted in infectious diseases department of Tangdu Hospital from 2013 to 2019[J]. Clinical Research and Practice(临床医学研究与实践), 2020, 5(10): 1-2, 5. [6] MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis[J]. BMC Med, 2014, 12: 145. [7] NEVENS F, BITTENCOURT PL, COENRAAD MJ, et al.Recomm-endations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis[J]. Dig Dis Sci, 2019, 64(6): 1419-1431. [8] KRAG A, BORUP T, MØLLER S, et al. Efficacy and safety of terlipr-essin in cirrhotic patients with variceal bleeding or hepatorenal syndrome[J]. Adv Ther, 2008, 25(11): 1105-1140. [9] CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992. [10] GERBES AL, HUBER E, GÜLBERG V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration[J]. Gastroenterology, 2009, 137(3): 1179. [11] CAVALLIN M, FASOLATO S, MARENCO S, et al.The treatment of hepatorenal syndrome[J]. Dig Dis, 2015, 33(4): 548-554. [12] GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Terlipr-essin for hepatorenal syndrome[J]. Cochrane Database Syst Rev, 2012(9): CD005162. [13] OZEL COSKUN BD, KARAMAN A, GORKEM H, et al.Terlipressin-induced ischemic skin necrosis: a rare association[J]. Am J Case Rep, 2014, 15: 476-479 [14] KIM HR, LEE YS, YIM HJ, et al.Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome[J]. Clin Mol Hepatol, 2013, 19(4): 417-420. [15] ŠÍMA M, POKORNÝ M, PAĎOUR F, et al. Terlipressin induced severe hyponatremia[J]. Prague Med Rep, 2016,117(1): 68-72. |